Previous 10 | Next 10 |
Amarin saw a major price drop recently. This follows the earnings miss and the suspended guidance. While the company is making every effort, the true cure is in a sell. Amarin ( AMRN ) is back in the news again, with the latest being the mineral oil bogey being raise...
3 Tips for Buying Penny Stocks in July 2022 When it comes to buying penny stocks, there are a few things you should know in order to make the most informed decision possible. The most crucial aspect when it comes to trading penny stocks is to know what you’re buying. Itȁ...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) announced on Thursday that serum samples of patients treated with its heart disease drug icosapent ethyl (IPE) had only limited differences in certain biomarkers compared to those who received a placebo. Previous d...
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an explo...
The shares of commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) dropped sharply on Thursday after Stat News raised concerns over the effectiveness of its heart disease therapy Vascepa. Following a new analysis, the report said that multiple experts called for cl...
HLS Therapeutics said it signed product listing agreements (PLA) with New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) for First Nations and Inuit peoples, for public reimbursement of heart drug Vascepa on their respective public prescription drug insurance...
Sarissa intends to "Abstain" given ongoing engagement with Amarin to add shareholder representatives to the board Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN) regarding how it intends to v...
The shares of commercial stage biotech Amarin Corporation (NASDAQ:AMRN) gained in the pre-market Friday after the company announced positive recommendation in the U.K. for reimbursement of heart disease therapy Vazkepa (icosapent ethyl). UK’s National Institute for Health and Care Exce...
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA ® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
2024-07-31 14:15:16 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Dayforce Inc. (DAY) is expected to report $0.18 for Q2 2024 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.44 for Q2 2024 Aurora Innovation Inc. (AUR) is expected to report for Q2 2024 Autohome Inc. American Depositary Shares each repr...
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...